Welcome to our dedicated page for Incannex Healthcare SEC filings (Ticker: IXHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Incannex Healthcare's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Incannex Healthcare's regulatory disclosures and financial reporting.
Incannex Healthcare Inc. (IXHL) reported a broad corporate update covering clinical progress, intellectual property and capital resources. The company has begun dosing patients in DReAMzz, a Phase 2 crossover dose‑optimization study of IHL‑42X for obstructive sleep apnea at 13 U.S. sites under Institutional Review Board approval, with an FDA‑reviewed protocol intended to support a later Phase 3 registration program.
Incannex highlighted prior positive Phase 2 RePOSA data in 121 subjects, where both low‑ and high‑dose IHL‑42X showed statistically significant improvements versus placebo in apnea‑hypopnea index and oxygen desaturation index, and noted the program’s Fast Track designation granted in December 2025. The U.S. Patent and Trademark Office has granted a composition and methods patent for IHL‑42X expiring July 9, 2040.
The company also reported progress for PSX‑001, its synthetic psilocybin candidate for generalized anxiety disorder, backed by a 73‑subject positive Phase 2 study, an open U.S. Investigational New Drug application for a Phase 2b trial, and recent regulatory engagement in the UK. As of August 31, 2026, Incannex held approximately $70 million in cash and cash equivalents with no debt, supported by more than A$11.2 million in 2026 Australian R&D tax incentive refunds.
Incannex Healthcare Inc. (IXHL) reports a clinical milestone for its lead sleep apnea candidate IHL-42X. The company has dosed the first patient in DReAMzz, a Phase 2 crossover dose-optimization study evaluating an oral fixed-dose combination of dronabinol and acetazolamide for obstructive sleep apnea.
The new study follows the earlier Phase 2 RePOSA trial, where IHL-42X produced statistically significant reductions in apnea-hypopnea index (AHI) versus placebo, with individual AHI reductions of up to 83% and an exceptional safety profile. IHL-42X has FDA Fast Track designation, and Incannex has activated 14 clinical sites in the United States for DReAMzz, with drug manufactured and regulatory and operational preparations completed.
DReAMzz is intended to characterize dose-response, optimize the treatment regimen, and support the design of a planned Phase 3 program. Incannex highlights IHL-42X as a potential oral treatment option for the large population affected by obstructive sleep apnea and positions this Phase 2 work as a step toward late-stage development.
Polar Asset Management Partners Inc., an Ontario, Canada-based investment advisor, reported beneficial ownership of Incannex Healthcare Inc. common stock. The position relates to 900,000 shares issuable upon the exercise of warrants, representing 7.0% of Incannex’s common stock class. Polar reports sole voting and sole dispositive power over these 900,000 warrant-linked shares, with no shared voting or dispositive power. The shares are directly held by Polar Multi-Strategy Master Fund, a Cayman Islands exempted company, for which Polar acts as investment advisor.
Incannex Healthcare Inc. reported receiving a final A$5,102,788.30 cash refund under the Australian Government’s Research and Development Tax Incentive Program, following approval of its overseas findings and amendment of its FY25 income tax return. Together with a previously received A$6,039,162.43 refund, the company has obtained more than A$11.2 million in non-dilutive capital during 2026.
The company states that this funding enhances its strong cash position and debt-free balance sheet, providing additional financial flexibility to advance its clinical pipeline, including IHL-42X, IHL-675A and PSX-001, while pursuing shareholder-focused capital allocation initiatives.
Incannex Healthcare Inc. has begun screening participants in its DReAMzz randomized, crossover Phase 2 dose confirmation study of IHL-42X for obstructive sleep apnea. The first group of trial sites has approvals to screen patients, with additional sites to start as further approvals are obtained.
IHL-42X previously received Fast Track designation from the U.S. FDA. An earlier Phase 2 study showed statistically significant reductions in Apnea-Hypopnea Index versus placebo, with reductions of up to 83%, and improvements in patient‑reported outcomes such as fatigue and sleep-related impairment while maintaining a favorable safety profile.
DReAMzz is designed to optimize dosing and further link objective sleep metrics with patient-reported outcomes, generating data intended to support Phase III development and strengthen both the regulatory and commercial positioning of IHL-42X in a condition affecting an estimated one billion people globally.
Incannex Healthcare Inc. reports that the U.S. Patent and Trademark Office has granted a key patent titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea” covering its proprietary IHL-42X oral combination therapy and related treatment methods. The patent has a baseline expiry date of 9 July 2040, and the company is exploring the potential for patent term extension following possible U.S. FDA approval. IHL-42X already has FDA Fast Track designation and positive Phase II data, and is advancing toward the DReAMzz Phase 2 dose optimisation study, which is intended to refine dosing and inform a planned Phase III program. Incannex describes obstructive sleep apnoea as a substantially underserved condition affecting an estimated one billion people globally, and views the strengthened U.S. patent position and ongoing clinical progress as enhancing the long-term commercial and strategic value of IHL-42X.
Incannex Healthcare Inc. reported receiving A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program for FY25 and expects a further approximately A$5.1 million in 2026. Combined, management highlights more than A$11.1 million in non-dilutive funding arriving in 2026.
The company notes that this cash is being received without issuing additional shares or taking on debt, supporting its debt-free balance sheet and existing cash position. Management states that the proceeds will help advance key clinical programs, including the DReAMzz study for lead candidate IHL-42X in obstructive sleep apnea, as well as IHL-675A for inflammatory conditions and PSX-001 for generalized anxiety disorder, while also supporting an active share repurchase program.
Incannex Healthcare Inc. filed a current report highlighting that Alliance Global Partners has initiated independent equity research coverage on the company. The AGP report reviews Incannex’s clinical pipeline, strategy, market opportunities and growth prospects, including lead programs IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder.
Incannex views this research coverage as an important step in expanding awareness of its clinical programs among institutional and retail investors. The company notes that analyst opinions are solely those of Alliance Global Partners, that AGP has received compensation for providing investment banking services, and includes customary forward-looking statement and risk factor cautions.
Incannex Healthcare Inc. reported no revenue and a net loss of $3.9M for the quarter and $16.8M for the nine months ended March 31, 2026. Operating expenses totaled $4.0M for the quarter, with research and development at $0.3M and general and administrative at $3.7M, the latter driven largely by higher stock-based compensation.
Cash and cash equivalents rose to $74.5M as of March 31, 2026, up from $15.0M at June 30, 2025, mainly due to equity financings including a $10.0M March 2026 registered direct offering. Stockholders’ equity increased to $75.2M. The company effected a 1-for-30 reverse stock split in February 2026.
Incannex continues to incur operating losses but believes its cash will fund operations for at least twelve months. It also has a $20M share repurchase program and has repurchased 2.1M shares to date for about $9.1M. Management discloses an ongoing material weakness in internal control over financial reporting and is implementing remediation measures.
Incannex Healthcare Inc. has officially started its DReAMzz clinical study of IHL-42X for obstructive sleep apnea. This crossover dose-optimization trial aims to refine the dosing profile and inform the design of a planned Phase III program.
The company has identified all 14 clinical sites, completed manufacturing of IHL-42X drug product, secured necessary import and export permits, and onboarded a global distribution partner to support site activation and patient dosing. DReAMzz builds on the prior Phase II RePOSA trial, where IHL-42X showed statistically significant and clinically meaningful reductions in apnea-hypopnea index, with improvements in oxygenation, sleep quality, fatigue and other patient-reported outcomes.
IHL-42X has previously received U.S. FDA Fast Track designation for obstructive sleep apnea, reflecting the seriousness of the condition and unmet medical need. DReAMzz is intended to further optimize and de-risk the Phase III pathway and forms part of Incannex’s broader strategy to develop combination therapies for chronic conditions.